39,685 Shares in Doximity, Inc. (NASDAQ:DOCS) Acquired by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP acquired a new position in Doximity, Inc. (NASDAQ:DOCS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 39,685 shares of the company's stock, valued at approximately $2,119,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Global Retirement Partners LLC lifted its stake in Doximity by 468.1% during the 4th quarter. Global Retirement Partners LLC now owns 534 shares of the company's stock valued at $29,000 after acquiring an additional 440 shares during the period. UMB Bank n.a. lifted its position in Doximity by 69.1% during the fourth quarter. UMB Bank n.a. now owns 575 shares of the company's stock valued at $31,000 after purchasing an additional 235 shares during the period. Larson Financial Group LLC lifted its position in Doximity by 49.4% during the fourth quarter. Larson Financial Group LLC now owns 756 shares of the company's stock valued at $40,000 after purchasing an additional 250 shares during the period. Optimum Investment Advisors purchased a new stake in Doximity in the fourth quarter worth approximately $43,000. Finally, Morse Asset Management Inc bought a new stake in Doximity in the 3rd quarter worth approximately $46,000. 87.19% of the stock is owned by institutional investors.

Doximity Price Performance

DOCS traded up $1.07 during midday trading on Monday, reaching $53.92. 252,256 shares of the company's stock were exchanged, compared to its average volume of 1,973,277. Doximity, Inc. has a 1-year low of $22.96 and a 1-year high of $85.21. The stock has a market capitalization of $10.07 billion, a PE ratio of 53.92, a P/E/G ratio of 4.10 and a beta of 1.41. The business's 50-day moving average price is $64.74 and its 200 day moving average price is $55.58.

Insiders Place Their Bets

In other news, Director Timothy S. Cabral sold 20,000 shares of the firm's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $57.62, for a total value of $1,152,400.00. Following the transaction, the director now owns 6,360 shares of the company's stock, valued at approximately $366,463.20. This trade represents a 75.87 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 37.40% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on DOCS shares. Wells Fargo & Company reaffirmed an "equal weight" rating on shares of Doximity in a research report on Friday, February 7th. Raymond James reiterated an "outperform" rating and set a $83.00 price target (up previously from $65.00) on shares of Doximity in a research note on Friday, February 7th. Truist Financial decreased their target price on Doximity from $65.00 to $58.00 and set a "hold" rating on the stock in a report on Thursday. The Goldman Sachs Group lifted their price objective on Doximity from $58.00 to $80.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Finally, Mizuho raised their target price on shares of Doximity from $55.00 to $65.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Eleven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $64.72.

Doximity Company Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.